Evidence map›Paper›PMID 42555635›Full record

ArticlePLoS pathogens2026

Candida albicans activates Staphylococcus aureus virulence regulatory systems to drive toxin-mediated human cell death.

Kara R Eichelberger, Ravishankar Chandrasekaran, Nicholas A Podar, Jia A Mei, Jacob M Curry, Saikat Paul, Julie A Bastarache, Victor J Torres, Paul L Fidel, Brian M Peters and 1 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

  • Update of
    2025
5 · Who and what money

Authors and funding

11 authors.

Kara R EichelbergerDepartment of Pediatrics, Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.ORCID 0000-0003-4532-9486
Ravishankar ChandrasekaranDepartment of Host-Microbe Interactions, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Nicholas A PodarBiomedical Engineering Program, School of Engineering, Vanderbilt University, Nashville, Tennessee, United States of America.
Jia A MeiDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Jacob M CurryDepartment of Pediatrics, Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Saikat PaulDepartment of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America.
Julie A BastaracheDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Victor J TorresDepartment of Host-Microbe Interactions, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Paul L FidelDepartment of Oral and Craniofacial Biology, Louisiana State University Health - School of Dentistry, New Orleans, Louisiana, United States of America.
Brian M PetersDepartment of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America.
James E CassatDepartment of Pediatrics, Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.ORCID 0000-0002-1199-1167

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
Mechanistic Studies Of The Staphylococcus aureus LukAB CytotoxinR01AI099394 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Victor J. Torres · 2013 to 2026
$6.1M
Contribution of LukED to Staphylococcus aureus pathobiologyR01AI105129 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI TORRES, VICTOR J. · 2014 to 2023
$4.9M
Applying Innovative Lung Mapping Strategies to Understand Alveolar Capillary Barrier Permeability in ARDSR35HL150783 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Julie A. Bastarache · 2020 to 2026
$4.6M
Childhood Infections Research ProgramT32AI095202 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JAMES E CASSAT · 2011 to 2026
$4.2M
Chemical Biology of Infectious Diseases (CBID) Training ProgramT32AI112541 · NIAID · VANDERBILT UNIVERSITY · PI Eric P Skaar · 2015 to 2026
$4.0M
Functional Antibody Repertoire Against S. aureus Leukocidins after Invasive Human InfectionR01AI139172 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E · 2019 to 2023
$3.5M
Differential Inflammasome Regulation in the pathogenesis of S. aureus osteomyelitisR01AI161022 · NIAID · WASHINGTON UNIVERSITY · PI CASSAT, JAMES E, MBALAVIELE, GABRIEL · 2021 to 2025
$3.4M
Neuroinflammatory mechanisms underlying sepsis-induced cognitive dysfunctionRF1AG075341 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BASTARACHE, JULIE A., HARRISON, FIONA EDITH · 2022 to 2025
$3.3M
Fungal-bacterial dynamics driving dysregulated host responses and lethal synergismR01AI177615 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI JAMES E CASSAT, PAUL L FIDEL · 2024 to 2026
$2.4M
Mechanisms of antibiotic failure during osteomyelitisR01AI173795 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JAMES E CASSAT · 2023 to 2026
$2.2M
NCATS NIH HHS UL1 TR002243NHLBI NIH HHS R35 HL150783NIAID NIH HHS R01 AI099394NIAID NIH HHS R01 AI105129NIAID NIH HHS R01 AI139172NIAID NIH HHS R01 AI161022NIAID NIH HHS R01 AI173795NIAID NIH HHS R01 AI177615NIAID NIH HHS T32 AI095202NIAID NIH HHS T32 AI112541NIA NIH HHS RF1 AG075341
6 · The paper itself

Abstract

Co-infection with Staphylococcus aureus and Candida albicans leads to worsened disease severity compared to mono-microbial infection. Because our understanding of the mechanisms driving enhanced disease severity during co-infection is incomplete, we sought to evaluate how interactions with C. albicans regulate S. aureus virulence toward host cells. We determined that C. albicans enhances S. aureus cytotoxicity toward both murine and human monocytes. These data revealed that enhanced murine monocyte cell death requires the S. aureus Agr virulence regulatory system, and cell death is driven by α-type phenol soluble modulins and γ-hemolysin. Unexpectedly, upon testing human monocytes we discovered that C. albicans induces robust cytotoxicity of an S. aureus agr mutant (Δagr), which is completely non-toxic in mono-culture and toward murine cells. Human neutrophils are also susceptible to this cytotoxicity. Using reporter strains and combinatorial mutants, we identified that co-culture activates the SaeRS regulatory system in S. aureus, and SaeRS is required for human-specific cytotoxicity. We further discovered that the SaeRS-regulated toxin Panton-Valentine Leukocidin (PVL) drives S. aureus Δagr cytotoxicity following co-culture. We observed similar cytotoxicity phenotypes using clinical isolates of both S. aureus and C. albicans, demonstrating broad conservation of this interaction. Finally, using mice that express the human isoform of the PVL receptor, we found that C. albicans enhances virulence of S. aureus Δagr during co-infection. Overall, this study determined that C. albicans enhances S. aureus toxin-mediated host cell death, and co-culture engages a major virulence regulatory system in a typically non-toxic S. aureus strain to induce potent human-selective cytotoxicity.

Indexed as

Bacterial ToxinsCandida albicansCandidiasisStaphylococcal InfectionsStaphylococcus aureusAnimalsBacterial ProteinsCell DeathCoculture TechniquesCoinfectionExotoxinsHemolysin ProteinsHumansLeukocidinsMiceMonocytesAgr protein, Staphylococcus aureusBacterial ProteinsBacterial ToxinsExotoxinsHemolysin ProteinsLeukocidinsPanton-Valentine leukocidinProtein KinasesSaeR protein, Staphylococcus aureusSaeS protein, Staphylococcus aureusTrans-ActivatorsTranscription Factors

Identifiers

PMID42555635
PMCPMC13475977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.